The pharmaceutical industry is
one of the most dynamic industries and has been constantly evolving. But recent
advances in medical technologies, drug discovery and biotechnology has further
accelerated this evolution and change in the pharma industry. Although the
industry is constantly evolving, the business models of the pharma industry can
be divided broadly into three phases.
Initially the pharma companies
heavily relied on one or few drug compounds that generated majority of revenue.
These were popularly called as “blockbuster” drugs, for instance Viagra was a
blockbuster drug for Pfizer. These blockbuster drugs were patent protected and
companies owning these patents enjoyed the exclusive profits. This was called
the Pharma 1.0 model or the “blockbuster model”. But as the patents begin to
expire and small biotech companies started to emerge and compete with
traditional pharma companies a wave of business remodeling came along. The pharma
companies started to replenish their product pipelines by acquiring these
biotech companies and started to diversify their portfolio. Companies started
to enter different areas like consumer products, animal health, specific
therapeutic areas like oncology and diabetes. This second phase was the
cost-efficient and diversified portfolio model called Pharma 2.0. Even though
pharma companies are still trying to adjust and succeed in this model, there is
another wave of change that is approaching. This is Pharma 3.0.
![]() |
| The Pharma 3.0 Model (Source: Ernst and Young, Progressions) |
The pharmaceutical industry is
witnessing the entry of non-traditional players like health IT companies,
mobile app companies, and many other players enter into the traditional pharma
industry. There has been a total investment of about USD 20 billion by these
new entrants in the pharma industry. These investments are focused on improving
patient experience and providing additional services. In addition, pharma
companies continue to struggle with expiration of existing patents. In next
five years almost USD 70 billion worth of drugs will lose their patents. Simultaneously
the patient (consumer in this case) is getting more and more educated and
informed, and has therefore started to demand more services and benefits for
their money. Interestingly, the new non-traditional players are successfully
serving to these new demands, like mobile apps for monitoring a disease or
social media platforms to generate awareness and network people with similar
diseases. These advances present significant challenge and at the same time a
unique opportunity for the traditional pharma companies to adapt to this
rapidly changing industry. In the Pharma 3.0 model, as Ernst and Young
explains- “The companies will succeed or fail based not just on how many units
of a product they sell, but rather on their ability improve health outcomes,
with patients and payers squarely in the middle.”
The pharma companies need to
remodel and innovate new business strategies. The primary step would be to
shift focus to put the patient at the center of the business model and focus on
providing healthy-outcomes for the patients. This will involve making new
collaborations, especially with new entrants in pharma industry, driving the
brand value from customer experience rather than product efficacy, and innovative
partnerships. This wave of change will make sure that only those companies that
are able to adapt fast to this change will survive. This might not be a very
good news for traditional pharma companies but is a definitely good sign of
change for the patient and consumers.
References:
- Progressions: Building Pharma 3.0. E&Y. 2012.
- Beyond Borders: Global Biotechnology Report. E&Y. 2012
- Pharma 3.0: A call for collaboration and experimentation. PharmaVoice. Vol 11. Number 6. June 2011





